The Mayo Clinic trial was supposed to provide crucial validation of the device’s reliability in detecting the FHR and ease of use compared to a standard handheld fetal doppler. (Mayo’s earlier study had concluded that the doppler was not economic due mainly to the cost of nurses directing patients). Disappointingly, the Herabeat was found to be both less reliable and more difficult to use than the standard handheld doppler.
I sold 80% of my holding upon publication of the results in Feb/March. If the company can prove that the poor results are no impediment to sales, I’ll jump back in. I note, however, that there has been no sales progress since the results were published, and the company has avoided addressing the issue.
- Forums
- ASX - By Stock
- Why no news from joondalup and us?
The Mayo Clinic trial was supposed to provide crucial validation...
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add HMD (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.181M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
HMD (ASX) Chart |
Day chart unavailable
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online